Skip to content

EBITDA at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$25.58M+193%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$9.1M+35.1%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$44.71M-6.7%
Zymeworks logo
ZymeworksZYME
-$45.98M-99.8%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$161M-20.1%
Royalty Pharma logo
Royalty PharmaRPRX

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Calculated from XOMA Corporation’s reported figures.

$480.0Kebit+
$892.0KDepreciation Depletion & Amortization
=$412K

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's EBITDA?
XOMA Corporation (XOMA) reported EBITDA of $412K in Q1 2026.
How has XOMA Corporation's EBITDA changed year-over-year?
XOMA Corporation's EBITDA decreased by 93.6% year-over-year, from $6.47M to $412K.
What is the long-term trend for XOMA Corporation's EBITDA?
Over 3 years (2022 to 2025), XOMA Corporation's EBITDA has grown at a -6.1% compound annual growth rate (CAGR), from -$17.32M to $14.35M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.